Serum 25-hydroxyvitamin D levels are associated with prognosis in hematological malignancies

Figures & data

Table 1. Serum 25(OH)D levels according to patients characteristics

Characteristics	Number of patients	Mean 25(OH)D level±SD (ng/ml)
Sex
Male	55	23·3±10·5
Female	50	24·3±13·7
Age
<30 years	12	22·0±7·6
30–60 years	50	23·8±11·4
>60 years	43	22·0±10·0
Diagnosis
AML	54	21·6±8·1
At diagnosis	23	18·6±6·6
In CR<3 years	8	23·0±8·4
In CR>5 years	11	28·5±6·2
At relapse	12	19·9±9·1
ALL	9	18·7±9·2
At diagnosis	4	12·0±4·3
In CR<3 years	3	18·3±3·5
In CR>5 years	2	33·0±4·2
MPS	20	25·9±12·8
CML	19	26·6±12·8
Thrombocytemia	1	13·0
MDS	8	22·5±10·5
Monoclonal gammapathy	10	22·5±15·1
MM at diagnosis	2	11·5±0·7
MM in partial response	3	20·6±5·5
MM at relapse	1	23·0
MGUS	4	28·5±23·1
Other chronic lymphoid disorders	4	37·0±0·8
CLL	2	37·5±0·7
LNH	2	36·5±0·7
Disease stage
Active disease	80	21·9±11·1
At diagnosis	37	19·1±8·6
Chronic phase	30	26·2±13·4
In relapse	13	20·1±8·7
Complete response	25	25·9±7·5
Since less than 3 years	12	22·4±7·5
Since more than 5 years	13	29·2±6·1
Overall	105	22·9±10·5

Figure 1. Correlations between outcome and 25(OH)D levels are illustrated by (A) the relationship between 25(OH)D levels and the stage of the disease in acute leukemias: patients at the time of diagnosis (n = 27), patients with CR of less than 3 years (n = 11), patients with CR of more than 5 years (n = 13), and patients in relapse (n = 12); and (B) the relationship between 25(OH)D levels and molecular response in leukemias with Philadelphia chromosome: patients with no major response (n = 12), and patients with major response (n = 13).